Laurence Jerome M, Wang Chuanmin, Zheng Maolin, Cunningham Sharon, Earl John, Tay Szun Szun, Allen Richard D M, McCaughan Geoffrey W, Alexander Ian E, Bishop G Alex, Sharland Alexandra F
Collaborative Transplantation Research Group, Royal Prince Alfred Hospital and University of Sydney, Sydney, Australia.
Liver Transpl. 2009 Feb;15(2):233-41. doi: 10.1002/lt.21662.
The aim of this study was to evaluate the ability of local overexpression of indoleamine dioxygenase (IDO) to abrogate rat liver transplant rejection by the use of an adeno-associated virus vector [recombinant adeno-associated virus 2/8 (rAAV2/8)] to deliver the transgene to the allograft prior to transplantation. A green fluorescent protein (GFP)-expressing vector [recombinant adeno-associated virus 2/8-liver-specific promoter 1-enhanced green fluorescent protein (rAAV2/8-LSP1-eGFP)] was used to examine the kinetics of expression and optimal dosing for transduction of Piebald Virol Glaxo (PVG) rat livers. A vector encoding the rat IDO gene (rAAV2/8-LSP1-rIDO) was constructed and tested by its ability to induce tryptophan catabolism and kynurenine production in vitro and in vivo. PVG donor rats were injected, via the portal vein, with rAAV2/8-LSP1-rIDO 2 weeks before transplantation into PVG strain isograft or Lewis (LEW) strain allograft recipients. With the enhanced GFP vector, 29.5% and 47.4% of hepatocytes were found to express GFP at 3 and 6 weeks after injection, respectively. In untransplanted PVG animals, the rAAV2/8-LSP1-rIDO vector induced, 3 weeks after administration, a 1.8-fold increase (P = 0.0161) in liver IDO activity, which was associated with a fall in serum tryptophan to 0.5 times the baseline level (P < 0.001). PVG recipients of PVG liver isografts pretreated with the IDO-expressing vector had a 45% lower level of serum tryptophan than recipients of isografts pretreated with the GFP-expressing vector (P = 0.03). LEW recipients of PVG liver allografts pretreated with the rat IDO vector had a median survival time of 12 days, whereas recipients of allografts pretreated with rAAV2/8-LSP1-eGFP had a median survival time of 13 days (P = 0.38). Both groups displayed similar histological features of acute cellular rejection. In conclusion, rAAV2/8 vectors produce highly efficient, though delayed, hepatocyte transduction in vivo and provide a useful gene delivery tool for transplantation models. However, gene delivery using IDO was unsuccessful in prolonging rat liver allograft survival.
本研究的目的是评估通过使用腺相关病毒载体[重组腺相关病毒2/8(rAAV2/8)]在移植前将转基因递送至同种异体移植物,使吲哚胺双加氧酶(IDO)在局部过表达以消除大鼠肝移植排斥反应的能力。使用表达绿色荧光蛋白(GFP)的载体[重组腺相关病毒2/8-肝脏特异性启动子1-增强型绿色荧光蛋白(rAAV2/8-LSP1-eGFP)]来检测花斑病毒-维洛格拉克索(PVG)大鼠肝脏转导的表达动力学和最佳剂量。构建了编码大鼠IDO基因的载体(rAAV2/8-LSP1-rIDO),并通过其在体外和体内诱导色氨酸分解代谢和犬尿氨酸产生的能力进行测试。在移植到PVG品系同基因移植或刘易斯(LEW)品系同种异体移植受体之前2周,通过门静脉向PVG供体大鼠注射rAAV2/8-LSP1-rIDO。使用增强型GFP载体时,在注射后3周和6周分别发现29.5%和47.4%的肝细胞表达GFP。在未移植的PVG动物中,rAAV2/8-LSP1-rIDO载体在给药后3周诱导肝脏IDO活性增加1.8倍(P = 0.0161),这与血清色氨酸降至基线水平的0.5倍相关(P < 0.001)。用表达IDO的载体预处理的PVG肝脏同基因移植的PVG受体血清色氨酸水平比用表达GFP的载体预处理的同基因移植受体低45%(P = 0.03)。用大鼠IDO载体预处理的PVG肝脏同种异体移植的LEW受体的中位存活时间为12天,而用rAAV2/8-LSP1-eGFP预处理的同种异体移植受体的中位存活时间为13天(P = 0.38)。两组均表现出相似的急性细胞排斥组织学特征。总之,rAAV2/8载体在体内产生高效但延迟的肝细胞转导,并为移植模型提供了一种有用的基因递送工具。然而,使用IDO进行基因递送未能成功延长大鼠肝脏同种异体移植的存活时间。